Bruce Bowling, MD
Family Medicine · Endwell, NYNPI 1407881832
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $201 and has fallen 67.9% since, to $64 in 2025.
Across 54 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$143
- Abbott$116
- Lilly USA, LLC$96
- Takeda Pharmaceuticals U.S.A., Inc.$79
- Pfizer$66
- Merck$54
- plus $304 from 15 others
Across 25 payments — averaging $11,452 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$286K
What the payments were for
- Food & beverage$857100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 8 | $143 |
| Abbott | 8 | $116 |
| Lilly USA, LLC | 5 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $79 |
| Pfizer | 5 | $66 |
| Merck | 3 | $54 |
| AstraZeneca | 3 | $51 |
| AbbVie(2 entities) | 2 | $40 |
| Amgen | 2 | $30 |
| Nevro Corp. | 1 | $24 |
| Novartis | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Si-bone, Inc. | 2 | $14 |
| GSK | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Corium, LLC | 1 | $12 |
| Radius Health, Inc. | 1 | $11 |
| Neuronetics, Inc. | 1 | $10 |
How this compares
$857 in reported general payments places this provider in the 65th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $69,189 |
| JardianceEmpagliflozin | 46 | $54,141 |
| EliquisApixaban | 22 | $30,400 |
| TrulicityDulaglutide | 14 | $20,284 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $17,201 |
| XareltoRivaroxaban | 18 | $16,738 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $10,421 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $9,350 |
| Atorvastatin Calcium | 149 | $1,820 |
| Levothyroxine Sodium | 55 | $1,149 |
| Duloxetine Hcl | 48 | $1,039 |
| Pantoprazole Sodium | 69 | $913 |
| Rosuvastatin Calcium | 63 | $830 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $815 |
| Omeprazole | 38 | $727 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $143 | $69,18936 claims |
| PfizerEliquis | $66 | $30,40022 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $13 | $27,62135 claims |
| Lilly USA, LLCTrulicity | $96 | $20,28414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,321 family medicine providers in New York.
Other family medicine in Endwell
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.